These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 28643307)

  • 1. [Application of magnetic resonance in "non-operative treatment" strategy for rectal cancer].
    Wang Y; Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):630-634. PubMed ID: 28643307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 3. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
    Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
    [No Abstract]   [Full Text] [Related]  

  • 5. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review.
    Joye I; Deroose CM; Vandecaveye V; Haustermans K
    Radiother Oncol; 2014 Nov; 113(2):158-65. PubMed ID: 25483833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
    Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognosis and complications of local excision for rectal cancer after neoadjuvant chemoradiotherapy].
    Li YH; Qiu XY; Lin GL; Zhou JL; Xiao Y; Qiu HZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):344-351. PubMed ID: 33878824
    [No Abstract]   [Full Text] [Related]  

  • 10. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 11. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
    Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
    Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection.
    Kim H; Myoung S; Koom WS; Kim NK; Kim MJ; Ahn JB; Hur H; Lim JS
    PLoS One; 2016; 11(1):e0146235. PubMed ID: 26730717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
    Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of lymph node status in rectal cancer by imaging].
    Wang Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):630-3. PubMed ID: 27353097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
    Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive value of combination of MRI tumor regression grade and apparent diffusion coefficient for pathological complete remission after neoadjuvant treatment of locally advanced rectal cancer].
    Xu N; Huang FC; Li WL; Luan X; Jiang YM; He B
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):359-365. PubMed ID: 33878826
    [No Abstract]   [Full Text] [Related]  

  • 17. MAGNETIC RESONANCE IMAGING TO EVALUATE NEOADJUVANT THERAPY EFFECTS ON RECTAL CARCINOMA.
    Sofić A; Vukobrat-Bijedić Z; Husić-Selimović A; Šehović N; Buija D; Eminagić D; Banjin M; Đuran A
    Acta Clin Croat; 2015 Sep; 54(3):303-8. PubMed ID: 26666099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
    Battersby NJ; Dattani M; Rao S; Cunningham D; Tait D; Adams R; Moran BJ; Khakoo S; Tekkis P; Rasheed S; Mirnezami A; Quirke P; West NP; Nagtegaal I; Chong I; Sadanandam A; Valeri N; Thomas K; Frost M; Brown G
    Trials; 2017 Aug; 18(1):394. PubMed ID: 28851403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of magnetic resonance imaging in assessing the efficacy of neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
    Wang Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar; 18(3):216-20. PubMed ID: 25809322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.